Jagsonpal Pharmaceuticals To Acquire India & Bhutan Business Of Yash Pharma Laboratories
The consideration would be paid in cash and would be paid from internal accruals
 (1)_20240519105017original_image_38.webp)
Jagsonpal Pharmaceuticals today unveiled that it has signed a business transfer agreement for the acquisition of the India and Bhutan business of Yash Pharma for Rs 92.47 crores.
The consideration would be paid in cash and would be paid from internal accruals. The Company had cash balance of Rs 135 crores as on 31 December 2023.
The transaction is subject to customary closing conditions and expected to close within 45 days.
Manish Gupta, Managing Director, Jagsonpal Pharmaceutical stated, “The acquisition of the India and Bhutan businesses of Yash Pharma aligns with our vision of becoming a stronger India-focussed healthcare business with multiple growth levers. As part of the transaction, company gets access to 30+ brands with 4 brands amongst the top-10 of their molecule category."
Growthally Advisors were the advisors for the transaction. ThinkLaw Advocates were the legal advisor while Deloitte Touche Tohmatsu India LLP were the financial diligence partner for Jagsonpal Pharmaceuticals Limited. Khaitan and Co were the legal advisor for Yash Pharma.
'This acquisition is a gateway to attractive, fast-growing Dermatology and Childcare segments, bolstering our presence in the Indian pharmaceutical market. We wholeheartedly welcome around 250 Yash Pharma employees to the growing Jagsonpal family. We will now focus on supporting the commercial leadership team to accelerate growth in business as well as leverage synergies," added Gupta.
